{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:26:35Z","timestamp":1793967995736,"version":"4.8.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tanimilast is a novel phosphodiesterase-4 inhibitor under clinical development for the maintenance therapy of asthma and chronic obstructive pulmonary disease (COPD). Since tanimilast is inhaled, it is important to evaluate lung deposition as part of its clinical development. The current study, therefore, used functional respiratory imaging, a validated, noninvasive quantification imaging methodology, to evaluate the lung deposition of tanimilast in patients with asthma or COPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study used data from 12 patients with asthma and 12 patients with COPD, primarily selected based on disease severity. Patients with COPD had chronic bronchitis,\u00a0with\u00a0minimal high-resolution computerized tomography evidence of emphysema. Total intrathoracic, central, distal, peripheral, and extrathoracic deposition of tanimilast 400 \u00b5g and 800 \u00b5g was evaluated using three inhalation profiles\u2014inhalation durations of 1, 2, and 3 seconds, with associated peak flows of 100, 60, and 45 L\/min, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Intrathoracic deposition as a percentage of the delivered dose was similar in asthma and COPD, with mean \u00b1 SD varying between 34.6\u2009\u00b1\u20098.5% and 44.9\u2009\u00b1\u20095.9%, increasing slightly with increasing inhalation duration (i.e., from 1 to 3 seconds), whereas extrathoracic deposition decreased progressively. Central deposition was low (&lt;5%) regardless of inhalation duration (2.7\u2009\u00b1\u20090.9% to 4.4\u2009\u00b1\u20091.6%). Distal deposition was similar with the two tanimilast doses and although not impacted by inhalation duration was slightly higher in COPD than asthma. Peripheral deposition increased with increasing inhalation duration (e.g., in asthma for tanimilast 400 \u00b5g, from 14.1\u2009\u00b1\u20093.6% for a duration of 1 second to 19.9\u2009\u00b1\u20094.0% for a duration of 3 seconds) and was higher in asthma than in COPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Tanimilast effectively reached all levels of the airway in patients with asthma or COPD. Peripheral deposition was enhanced by lower inspiratory flows (i.e., longer inhalation durations), suggesting that specific inhalation strategies may have the potential to improve therapeutic outcomes in obstructive lung diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/19412711251396759","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:42:36Z","timestamp":1763736156000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Lung Deposition of Tanimilast, an Inhaled Phosphodiesterase-4 Inhibitor, in Patients with Asthma or COPD, Evaluated Using Functional Respiratory Imaging"],"prefix":"10.1177","volume":"39","author":[{"given":"Navid Monshi","family":"Tousi","sequence":"first","affiliation":[{"name":"FLUIDDA NV, Kontich, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Osello","sequence":"additional","affiliation":[{"name":"Global Technical Development, Chiesi Farmaceutici SpA, Parma, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Santoro","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Campochiaro","sequence":"additional","affiliation":[{"name":"Global Technical Development, Chiesi Farmaceutici SpA, Parma, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.T.","family":"Bates","sequence":"additional","affiliation":[{"name":"University of Vermont, Burlington, Vermont, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Galkin","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"De Backer","sequence":"additional","affiliation":[{"name":"FLUIDDA Inc., New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosein","family":"Sadafi","sequence":"additional","affiliation":[{"name":"FLUIDDA NV, Kontich, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-2689","authenticated-orcid":false,"given":"Gwen","family":"Skloot","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"AstraZeneca UK Limited. DAXAS 500 micrograms film-coated tablets: Summary of product characteristics. 2024. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/5650\/smpc#gref [Last accessed: April2 2025]."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61255-1"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61252-6"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201607-1349OC"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2014.10.002"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13014"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S159827"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.099192"},{"key":"e_1_3_3_10_2","volume-title":"Ohtuvayre Prescribing Information","author":"Verona Pharma","year":"2024","unstructured":"Verona Pharma. Verona. Ohtuvayre Prescribing Information. Pharma: Raleigh, NC, USA; 2024."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1124\/DMD.124.001895"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.220541"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.220558"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S174156"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1142-7"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-1329-y"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01512-y"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2016.06.011"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.10100322"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1586\/17476348.2016.1136216"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56033-1"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.COMPBIOMED.2016.04.017"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2004.10.012"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1152\/JAPPLPHYSIOL.00008.2009"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.202207-1384OC"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1106955"},{"key":"e_1_3_3_27_2","unstructured":"Global Initiative For Asthma. Global strategy for asthma management and prevention. 2024. Available from: https:\/\/ginasthma.org\/2024-report\/ [Last accessed: April2 2025]."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.201110-1849OC"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.107.3_Supplement.140S"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/08958378.2010.547535"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.04.019"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2009.0772"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.11.036"}],"container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/19412711251396759","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19412711251396759","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19412711251396759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:49:06Z","timestamp":1781185746000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/19412711251396759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1177\/19412711251396759"],"URL":"https:\/\/doi.org\/10.1177\/19412711251396759","relation":{},"ISSN":["1941-2711","1941-2703"],"issn-type":[{"value":"1941-2711","type":"print"},{"value":"1941-2703","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]}}}